ABI family member 3 binding proteinGenealiases: NESHBP · TARSH
Q-omics provides the consensus-scored ABI3BP profile across patient tissues and cancer cell-line models. ABI3BP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABI3BP is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ABI3BP protein abundance shows 28,051 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where ABI3BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABI3BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABI3BP survival associations across molecular data types. ABI3BP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABI3BP RNA expression–survival associations across cancer types. High ABI3BP expression shows unfavorable associations in KICH, but favorable associations in KIRC, KIRP, ACC, LUAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABI3BP RNA expression.
This table summarizes ABI3BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ABI3BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABI3BP shows lower tumor expression in COAD, BLCA, KICH, THCA, LUSC and LUAD. The COAD box plot shows higher ABI3BP RNA expression in normal versus tumor tissue (log2 FC = −2.543, t-test p < 0.001).
This table shows molecular features associated with ABI3BP in patient tissues and cancer cell lines. In patient samples, ABI3BP shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ABI3BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
